Breast Cancer and Antinuclear Antibodies

Autoantibody testing must be carried out by a laboratory capable of implementing all the techniques required for detection and identification. All results must be interpreted according to the clinical context, which is why close collaboration between the prescribing physician and the biologist is essential. Indirect immunofluorescence remains the current screening technique for most autoantibodies.The risk of anti-nuclear antibodies in breast cancer patients needs to be thoroughly investigated in a study of 100 hospitalized patients to estimate the strength of the association between breast cancer and antibodies.Characteristic and pathological analyses of patients with positive antinuclear antibodies are not significant, but the antibodies found are very frequent in relation to patient numbers.We’re going to complete the follow-up of the patients by increasing their number to fully understand the relationship of the antibodies we found in our results.